NCT06450990View on ClinicalTrials.gov

Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

December 28, 2025

Study Completion Date

February 26, 2026

Conditions

Bacterial VaginosisVulvovaginal Candidiasis

Interventions

DRUG

BGY-1601-VT

Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.

OTHER

PLACEBO

Placebo